Cogent Biosciences, Inc. SEC filings

Filings

Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.

1. ROUTINE4Cogent Biosciences, Inc.COGTOct 5

   Cogent Biosciences reports director's stock option

   • Karen Jean Ferrante, director, received 759 stock options on 10/01/2026
   • Options granted under non-employee director compensation plan
   • Exercise price of $31.59, expires 10/01/2036

   Karen Jean Ferrante

2. ROUTINE8-KCogent Biosciences, Inc.COGTSep 2

   Current report

3. ROUTINE4Cogent Biosciences, Inc.COGTAug 31

   Arlene Morris, insider filing for COGT

   Arlene Morris, reporting

4. ROUTINE144Cogent Biosciences, Inc.COGTAug 27

   Arlene Morris, planned sale of COGT shares

   Arlene Morris, reporting

5. ROUTINESCHEDULE 13G/ACogent Biosciences, Inc.COGTAug 13

   Ownership stake disclosure by James E Flynn (amended)

   James E Flynn, filed by

6. ROUTINE8-KCogent Biosciences, Inc.COGTAug 10

   Current report

7. ROUTINE424B5Cogent Biosciences, Inc.COGTAug 10

   Securities offering

8. NOTABLE10-QCogent Biosciences, Inc.COGTAug 10

   Quarterly report

9. ROUTINE8-KCogent Biosciences, Inc.COGTAug 10

   Current report

10. ROUTINESCHEDULE 13GCogent Biosciences, Inc.COGTJul 31

    Ownership stake disclosure by VANGUARD CAPITAL MANAGEMENT LLC

    VANGUARD CAPITAL MANAGEMENT LLC, filed by

11. ROUTINESCHEDULE 13G/ACogent Biosciences, Inc.COGTJul 27

    Ownership stake disclosure by BlackRock, Inc. (amended)

    BlackRock, Inc., filed by

12. ROUTINE4Cogent Biosciences, Inc.COGTJul 6

    Karen Jean Ferrante, insider filing for COGT

    Karen Jean Ferrante, reporting

13. ROUTINE4Cogent Biosciences, Inc.COGTJun 11

    6 insider filings

    Peter Evan Harwin, insider filing for COGT

    Show all 6

    • 4Insider filing for COGTJun 11
    • 4Insider filing for COGTJun 11
    • 4Insider filing for COGTJun 11
    • 4Insider filing for COGTJun 11
    • 4Insider filing for COGTJun 11
    • 4Insider filing for COGTJun 11

    Peter Evan Harwin, reporting

14. ROUTINE8-KCogent Biosciences, Inc.COGTJun 11

    Current report

15. ROUTINE4Cogent Biosciences, Inc.COGTMay 21

    Andrew R Robbins, insider filing for COGT

    Andrew R Robbins, reporting

16. ROUTINESCHEDULE 13G/ACogent Biosciences, Inc.COGTMay 14

    Ownership stake disclosure by James E Flynn (amended)

    James E Flynn, filed by

17. NOTABLE10-QCogent Biosciences, Inc.COGTMay 5

    Quarterly report

18. ROUTINE8-KCogent Biosciences, Inc.COGTMay 5

    Current report

19. ROUTINEARSCogent Biosciences, Inc.COGTApr 23

    Annual report to shareholders

20. ROUTINEDEFA14ACogent Biosciences, Inc.COGTApr 23

    Additional proxy materials

21. ROUTINEDEF 14ACogent Biosciences, Inc.COGTApr 23

    Proxy statement

22. ROUTINE4Cogent Biosciences, Inc.COGTApr 3

    Karen Jean Ferrante, insider filing for COGT

    Karen Jean Ferrante, reporting

23. ROUTINE144Cogent Biosciences, Inc.COGTMar 31

    Fairmount Funds Management LLC, planned sale of COGT shares

    Fairmount Funds Management LLC, reporting

24. ROUTINE4Cogent Biosciences, Inc.COGTMar 31

    Fairmount Funds Management LLC, insider filing for COGT

    Fairmount Funds Management LLC, reporting

25. NOTABLESCHEDULE 13D/ACogent Biosciences, Inc.COGTMar 31

    Ownership stake disclosure by Fairmount Funds Management LLC (amended)

    Fairmount Funds Management LLC, filed by

26. ROUTINESCHEDULE 13G/ACogent Biosciences, Inc.COGTMar 26

    Ownership stake disclosure by VANGUARD GROUP INC (amended)

    VANGUARD GROUP INC, filed by

27. ROUTINESCHEDULE 13G/ACogent Biosciences, Inc.COGTFeb 17

    Ownership stake disclosure by Commodore Capital LP (amended)

    Commodore Capital LP, filed by

28. ROUTINES-8Cogent Biosciences, Inc.COGTFeb 17

    Employee stock plan registration

29. ROUTINESCHEDULE 13G/ACogent Biosciences, Inc.COGTFeb 17

    Ownership stake disclosure by Kynam Capital Management, LP (amended)

    Kynam Capital Management, LP, filed by

30. NOTABLE10-KCogent Biosciences, Inc.COGTFeb 17

    Annual report

31. ROUTINE8-KCogent Biosciences, Inc.COGTFeb 17

    Current report

32. ROUTINESCHEDULE 13G/ACogent Biosciences, Inc.COGTJan 30

    Ownership stake disclosure by VANGUARD GROUP INC (amended)

    VANGUARD GROUP INC, filed by

33. ROUTINE4Cogent Biosciences, Inc.COGTJan 22

    Fairmount Funds Management LLC, insider filing for COGT

    Fairmount Funds Management LLC, reporting

34. ROUTINE144Cogent Biosciences, Inc.COGTJan 22

    Fairmount Funds Management LLC, planned sale of COGT shares

    Fairmount Funds Management LLC, reporting

35. NOTABLESCHEDULE 13D/ACogent Biosciences, Inc.COGTJan 22

    Ownership stake disclosure by Fairmount Funds Management LLC (amended)

    Fairmount Funds Management LLC, filed by

36. ROUTINESCHEDULE 13G/ACogent Biosciences, Inc.COGTJan 21

    Ownership stake disclosure by BlackRock, Inc. (amended)

    BlackRock, Inc., filed by

37. ROUTINESCHEDULE 13G/ACogent Biosciences, Inc.COGTJan 21

    Ownership stake disclosure by BlackRock, Inc. (amended)

    BlackRock, Inc., filed by

38. ROUTINE4Cogent Biosciences, Inc.COGTJan 5

    Karen Jean Ferrante, insider filing for COGT

    Karen Jean Ferrante, reporting

39. ROUTINE4Cogent Biosciences, Inc.COGTDec 30, 2025

    4 insider filings

    John Edward Robinson, insider filing for COGT

    Show all 4

    • 4Insider filing for COGTDec 30, 2025
    • 4Insider filing for COGTDec 30, 2025
    • 4Insider filing for COGTDec 30, 2025
    • 4Insider filing for COGTDec 30, 2025

    John Edward Robinson, reporting

40. ROUTINE144Cogent Biosciences, Inc.COGTDec 29, 2025

    3 Form 144 notices

    Jessica Sachs, planned sale of COGT shares

    Show all 3

    • 144Planned insider sale of COGT sharesDec 29, 2025
    • 144Planned insider sale of COGT sharesDec 29, 2025
    • 144Planned insider sale of COGT sharesDec 29, 2025

    Jessica Sachs, reporting

Older filings on EDGAR